✦ LIBER ✦

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study

✍ Scribed by Tudor-Williams, G; Cahn, P; Chokephaibulkit, K; Fourie, J; Karatzios, C; Dincq, S; Opsomer, M; Kakuda, TN; Nijs, S; Tambuyzer, L; Tomaka, FL

Book ID: 121527942
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 276 KB
Volume: 15
Category: Article
ISSN: 1464-2662
DOI: 10.1111/hiv.12141

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of etravirine at wee

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

✍ Katlama, Christine; Clotet, Bonaventura; Mills, Anthony; Trottier, Benoit; Molin 📂 Article 📅 2010 🏛 International Medical Press 🌐 English ⚖ 228 KB

Safety and Efficacy of Dolutegravir in T

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

✍ Eron, J. J.; Clotet, B.; Durant, J.; Katlama, C.; Kumar, P.; Lazzarin, A.; Poizo 📂 Article 📅 2012 🏛 University of Chicago Press 🌐 English ⚖ 411 KB

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lal 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christi 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Efficacy and safety of darunavir-ritonav

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

✍ Bonaventura Clotet; Nicholas Bellos; Jean-Michel Molina; David Cooper; Jean-Chri 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 180 KB

Efficacy and safety of darunavir-ritonav

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

✍ José Valdez Madruga; Daniel Berger; Marilyn McMurchie; Fredy Suter; Denes Banheg 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB